C4 Therapeutics (CCCC) Long-Term Investments (2021 - 2026)
C4 Therapeutics (CCCC) posted quarterly Long-Term Investments of $32.6 million for Q1 2026, up 66.17% year-over-year from $19.6 million in Q1 2025, and down 32.87% quarter-over-quarter from $48.6 million in Q4 2025.
C4 Therapeutics (CCCC) Long-Term Investments (2021 - 2026) Analysis & Trends
C4 Therapeutics' Long-Term Investments history runs 6 years deep, the most recent figure standing at $32.6 million for Q1 2026.
- In Q1 2026, Long-Term Investments rose 66.17% year-over-year to $32.6 million; the TTM figure through Mar 2026 stood at $32.6 million (up 66.17% YoY), while the FY2025 annual figure was $48.6 million, up 117.2% from the prior year.
- Long-Term Investments for Q1 2026 stood at $32.6 million, down from $48.6 million in the prior quarter.
- The five-year high for Long-Term Investments was $130.5 million in Q1 2022, with the low at $7.9 million in Q3 2025.
- The 5-year median for Long-Term Investments is $31.6 million (2024), against an average of $40.4 million.
- The sharpest annual moves came in 2022 and 2023: Long-Term Investments surged 301.53% in 2022, then slumped 78.44% in 2023.
- C4 Therapeutics' Long-Term Investments stood at $61.0 million in 2022, then tumbled by 54.06% to $28.0 million in 2023, then slipped by 20.17% to $22.4 million in 2024, then surged by 117.2% to $48.6 million in 2025, then tumbled by 32.87% to $32.6 million in 2026.
- Business Quant data shows CCCC's Long-Term Investments at $32.6 million in Q1 2026, $48.6 million in Q4 2025, and $7.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 372.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.17 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | C4 Therapeutics | 521.12 Mn | 267.46 Mn | - | 46.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 46.79 Mn |
| Mar 31, 2026 | 32.60 Mn |
| Dec 31, 2025 | 48.56 Mn |
| Sep 30, 2025 | 7.88 Mn |
| Jun 30, 2025 | 8.42 Mn |
| Mar 31, 2025 | 19.62 Mn |
| Dec 31, 2024 | 22.36 Mn |
| Sep 30, 2024 | 28.76 Mn |
| Jun 30, 2024 | 31.64 Mn |
| Mar 31, 2024 | 40.98 Mn |
| Dec 31, 2023 | 28.01 Mn |
| Sep 30, 2023 | 29.86 Mn |
| Jun 30, 2023 | 19.42 Mn |
| Mar 31, 2023 | 34.71 Mn |
| Dec 31, 2022 | 60.96 Mn |
| Sep 30, 2022 | 52.36 Mn |
| Jun 30, 2022 | 90.06 Mn |
| Mar 31, 2022 | 130.48 Mn |
| Dec 31, 2021 | 142.20 Mn |
| Sep 30, 2021 | 78.19 Mn |